Phenotyping of N-acetyltransferase type 2 by caffeine from uncontrolled dietary exposure

European Journal of Clinical Pharmacology

Volumn 60, Issue 1, 2004, Pages 17-21

  Jetter, Alexander ^a   Kinzig Schippers, Martina ^b   Illauer, Michael ^b   Hermann, Robert ^c   Erb, Katharina ^d   Borlak, Jürgen ^e   Wolf, Helga ^f   Smith, Gillian ^f   Cascorbi, Ingolf ^g   Sörgel, Fritz ^b   Fuhr, Uwe ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Institute for Biomedical and Pharmaceutical Research   (Germany)

^c ALTANA Pharma   (Germany)

^d Clinphase Clinical Pharmacology Services   (Germany)

^e FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE   (Germany)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Arylamine; Caffeine; N acetyltransferase 2; Phenotype

Indexed keywords

1 METHYLURIC ACID; 1 METHYLXANTHINE; 5 ACETAMIDO 6 FORMYLAMINO 3 METHYLURACIL; ARYLAMINE ACETYLTRANSFERASE; CAFFEINE; CAFFEINE DERIVATIVE; COFFEINUM; DRUG METABOLITE; PERCOFFEDRINOL N;

ADULT; ARTICLE; DIETARY INTAKE; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; GENOTYPE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ACETYLATION; ADMINISTRATION, ORAL; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; CAFFEINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIET; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TIME FACTORS; URACIL; URIC ACID; XANTHINES;

EID: 11144356464     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0718-8     Document Type: Article

References (15)

1. Hirvonen A (1999) Polymorphic NATs and cancer predisposition. In: Vineis P, Malats N, Lang M, d'Errico A, Caporaso N, Cuzick J, Boffetta P (eds) Metabolic polymorphisms and susceptibility to cancer. International Agency for Research on Cancer, Lyon, pp 251-270
2. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB et al (1992) Determination of CYP1A2 and NAT 2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 2:116-127
3. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 6:121-149
4. Tang BK, Kadar D, Kalow W (1987) An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther 42:509-513
5. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W (1991) Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther 49:648-657
6. Grant DM, Tang BK, Kalow W (1984) A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol 17:459-464
7. Bendriss EK, Markoglou N, Wainer IW (2000) Liquid Chromatographic method for the simultaneous determination of caffeine and fourteen caffeine metabolites in urine. J Chromatogr B Biomed Sci Appl 746:331-338
8. Smith CA, Wadelius M, Gough AC, Harrison DJ, Wolf CR, Rane A (1997) A simplified assay for the arylamine N-acetyl-transferase 2 polymorphism validated by phenotyping with isoniazid. J Med Genet 34:758-760
9. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I (1995) Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 57:581-592
10. Bland JM, Altman DG (1999) Measuring agreement in method comparison studies. Stat Methods Med Res 8:135-160
11. Nyéki Á, Biollaz J, Kesselring UW, Décosterd LA (2001) Extractionless method for the simultaneous high-performance liquid chromatographic determination of urinary caffeine metabolites for N-acetyltransferase 2, cytochrome P450 1A2 and xanthine oxidase activity assessment. J Chromatogr B Biomed Sci Appl 755:73-84
12. Baud-Camus F, Marquet P, Soursac M, Davrinche A, Farinotti R (2001) Determination of N-acetylation phenotype using caffeine as a metabolic probe and high-performance liquid chromatography with either ultraviolet detection or electrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 760:55-63
13. Schneider H, Ma L, Glatt H (2003) Extractionless method for the determination of urinary caffeine metabolites using high-performance liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B 789:227-237
14. Wong P, Villeneuve G, Tessier V, Banerjee K, Nedev H, Jean-Claude BJ, Leyland-Jones B (2002) Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J Pharm Biomed Anal 28:693-700
15. Nyéki Á, Buclin T, Biollaz J, Decosterd LA (2003) NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs AAMU in the urine metabolite ratios. Br J Clin Pharmacol 55:62-67